APA (7th ed.) Citation

JA, K., P, M., CL, H., SF, M., MT, C., AJ, Z., . . . CG, W. (2023). Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma. Nature communications, 14(1), 2684. https://doi.org/10.1038/s41467-023-38342-7

Chicago Style (17th ed.) Citation

JA, Karam, et al. "Phase II Trial of Neoadjuvant Sitravatinib Plus Nivolumab in Patients Undergoing Nephrectomy for Locally Advanced Clear Cell Renal Cell Carcinoma." Nature Communications 14, no. 1 (2023): 2684. https://doi.org/10.1038/s41467-023-38342-7.

MLA (9th ed.) Citation

JA, Karam, et al. "Phase II Trial of Neoadjuvant Sitravatinib Plus Nivolumab in Patients Undergoing Nephrectomy for Locally Advanced Clear Cell Renal Cell Carcinoma." Nature Communications, vol. 14, no. 1, 2023, p. 2684, https://doi.org/10.1038/s41467-023-38342-7.